Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Jul-Sep;43(3):341-348.
doi: 10.1016/j.htct.2020.06.006. Epub 2020 Jul 6.

Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

Rodolfo D Cançado  1 , Aderson da Silva Araújo  2 , Alex Freire Sandes  3 , Celso Arrais  4 , Clarisse Lopes de Castro Lobo  5 , Maria Stella Figueiredo  6 , Sandra Fátima Menosi Gualandro  7 , Sara Teresinha Olalla Saad  8 , Fernando Ferreira Costa  8
Affiliations

Consensus statement for diagnosis and treatment of paroxysmal nocturnal haemoglobinuria

Rodolfo D Cançado et al. Hematol Transfus Cell Ther. 2021 Jul-Sep.

Abstract

Paroxysmal nocturnal hemoglobinuria is a chronic, multi-systemic, progressive and life-threatening disease characterized by intravascular hemolysis, thrombotic events, serious infections and bone marrow failure. Paroxysmal nocturnal hemoglobinuria results from the expansion of a clone of hematopoietic cells that due to an inactivating mutation of the X-linked gene PIG-A are deficient in glycosylphosphatidylinositol-linked proteins. Early diagnosis, using flow cytometry performed on peripheral blood, the gold standard test to confirm the diagnosis of paroxysmal nocturnal hemoglobinuria, is essential for improved patient management and prognosis. The traditional therapy for paroxysmal nocturnal hemoglobinuria includes blood transfusion, anti-thrombosis prophylaxis or allogeneic bone marrow transplantation. The treatment that has recently become available is the complement blockade by the anti-C5 monoclonal antibody eculizumab. In this consensus, we are aiming to review the diagnosis and treatment of the paroxysmal nocturnal hemoglobinuria patients, as well as the early recognition of its systemic complications. These procedures express the opinions of experts and have been based on the best available evidence and international guidelines, with the purpose of increasing benefits and reducing harm to patients.

Keywords: Consensus; Eculizumab; Hemoglobinuria; Paroxysmal.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Eculizumab PNH dosing schedule.
See this image and copyright information in PMC

References

    1. Brodsky R. Paroxysmal nocturnal hemoglobinuria. Blood. 2014;124(18):2804–2811. - PMC - PubMed
    1. Brodsky R.A. Narrative review: paroxysmal nocturnal hemoglobinuria: the physiology of complement-related hemolytic anemia. Ann Intern Med. 2008;148(8):587–595. - PubMed
    1. Strubing P. Paroxysmale haemoglobinurie. Dtsch Med Wochenschr. 1882;8:1–16.
    1. Enneking J. Eine neue form intermittierender haemoglobinurie (Haemoglobinuria paroxysmalis nocturia) Klin Wochenschr. 1928;7:2045.
    1. Ham T. Chronic hemolytic anemia with paroxysmal nocturnal hemoglobinuria. A study of the mechanism of hemolysisin relation to acid base equilibrium. N Engl J Med. 1937;217(23):915–917.